Abstract 278P
Background
Radiotherapy is an effective treatment option for local control of prostate cancer, but its role in the treatment of oligometastatic prostate cancer (omPCa) remains unclear. This study aimed to investigate the potential survival benefit of full-coverage radiotherapy in patients with omPCa.
Methods
A retrospective analysis was conducted on patients with omPCa who received full-coverage radiotherapy between July 2012 and June 2022. Full-coverage radiotherapy was defined as radiotherapy to all lesions, including the primary site and metastatic lesions. Overall survival (OS) was the primary endpoint, and biochemical progression-free survival (bPFS) and radiological progression-free survival (rPFS) were the secondary endpoint. The Kaplan-Meier method was used to estimate univariate analysis, and the log-rank test was used to conduct multivariate analysis.
Results
A total of 33 patients, including 31 de novo oligometastatic hormone-sensitive prostate cancer (omHSPC) patients and 2 oligometastatic castration-resistant prostate cancer (omCRPC) patients, were enrolled in the study. The median follow-up was 38.8 months (range: 4.2–70.6 months). The survival rates at 2, 3, and 5 years were 100%, 95.7%, and 81.2%, respectively. The median bPFS was 58.9 months (95% CI: 47.7 - 70.1 months). The median rPFS is 55.3 months (95% CI: 39.9 -70.8 months). According to the univariate analysis, TURP prior to radiotherapy, presence of symptoms related to the lesions, and the pre-radiotherapy status of CRPC were associated with poorer survival. Multivariate analysis showed EBRT synchronized with ADT or chemotherapy (p=0.016), non-CRPC status before radiotherapy(p=0.000), and PSA levels more than 1 ng/ml before radiotherapy ( p=0.014) may be associated with longer rPFS. Both univariate and multivariate studies have demonstrated that the coexistence of lymph node and bone metastases is associated with a higher risk of biochemical recurrence (p=0.02). The occurrence of acute adverse reactions of Grade 3 or higher was not observed.
Conclusions
Full-coverage radiotherapy with an optimistic bPFS and rPFS may improve the OS of patients with oligometastatic prostate cancer. Further prospective studies are warranted to confirm the findings of this retrospective analysis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Radiation Oncology, Shanghai Changhai Hospital, the Naval Medical Universit.
Funding
The First Affiliated Hospital of Navy Medical University “234 Subject Climbing Program” (2019YPT004), the First Affiliated Hospital of Naval Medical University “Youth Development Program”(2021JCQNO3).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract